Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc. (ALLO) Revenue
Annual & quarterly revenue history · segment & region breakdown
ALLO · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsAllogene Therapeutics, Inc. trailing twelve-month (TTM) revenue is $0.00B, a decrease of 100.00% year-over-year from $0.00B in FY2025.
Revenue trend
2025 – 2017 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.00B | -$0.00B | -100.00% |
| 2024-12-31 | $0.00B | -$0.00B | -76.84% |
| 2023-12-31 | $0.00B | -$0.00B | -39.10% |
| 2022-12-31 | $0.00B | -$0.11B | -99.86% |
| 2021-12-31 | $0.11B | +$0.11B | — |
| 2020-12-31 | $0.00B | +$0.00B | — |
| 2019-12-31 | $0.00B | +$0.00B | — |
| 2018-12-31 | $0.00B | +$0.00B | — |
| 2017-12-31 | $0.00B | — | — |
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Allogene Therapeutics, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Allogene Therapeutics, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Allogene Therapeutics, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
ALLO revenue · 4 questionsALLO's trailing twelve-month (TTM) revenue is $0.00B. That is a decrease of 100.00% year-over-year from $0.00B in FY2025.
▸ Source: FMP · Allogene Therapeutics, Inc. SEC filings · GAAP · Allogene Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026